MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

PASADENA 1-year open-label extension

G. Pagano, A. Reyes, A. Monnet, M. Martinec, N. Shariati, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Taylor, H. Svoboda, P. Fontoura, G. Kerchner, R. Doody, A. Bonni, T. Nikolcheva (Basel, Switzerland)

Meeting: 2023 International Congress

Abstract Number: 104

Keywords: Alpha-synuclein, Dopaminergic neurons, Parkinson’s

Category: Parkinson’s Disease: Clinical Trials

Objective: To describe the results of PASADENA 1-year open-label extension (OLE).

Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential to slow disease progression in Parkinson’s disease (PD). PASADENA (NCT03100149) is a multicentre, randomized, double-blind, placebo-controlled study evaluating the efficacy of prasinezumab in participants with early-stage PD.

Method: Participants with early-stage PD (diagnosis ≤2 years of age at screening; Hoehn & Yahr Stages I–II) were randomized to receive intravenous prasinezumab every 4 weeks (1500 mg or 4500mg) for two years (early-start group), or placebo for 52 weeks followed by prasinezumab (1500 mg or 4500 mg) for one year (delayed-start group). A total of 271 participants (out of the original 316) rolled over into a 5-year open-label extension, after a treatment-free period of 6 months on average. We describe here the continuous change from baseline at the end of 1-year open-label extension on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III, Part II, and  Part III+II, which was analyzed longitudinally using Mixed Model for Repeated Measures (MMRM) methodology. Participants were considered in the analysis regardless of the dose, type, or change of their symptomatic therapy. Real-world data were used as a comparator to put the results into context.

Results: Baseline characteristics were balanced between groups. Results from Part 3 will be described and put into context.

Conclusion: The PASADENA Part 3 OLE is currently ongoing, and we aim to describe the long-term safety and efficacy on a yearly basis.

To cite this abstract in AMA style:

G. Pagano, A. Reyes, A. Monnet, M. Martinec, N. Shariati, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Taylor, H. Svoboda, P. Fontoura, G. Kerchner, R. Doody, A. Bonni, T. Nikolcheva. PASADENA 1-year open-label extension [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/pasadena-1-year-open-label-extension/. Accessed May 24, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/pasadena-1-year-open-label-extension/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley